Igfbp3 (insulin-like growth factor binding protein 3) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Igfbp3 (insulin-like growth factor binding protein 3) Rattus norvegicus
Symbol: Igfbp3
Name: insulin-like growth factor binding protein 3
RGD ID: 2874
Description: Enables insulin-like growth factor II binding activity. Involved in several processes, including cellular response to Thyroglobulin triiodothyronine; cellular response to estradiol stimulus; and response to peptide hormone. Located in extracellular space and platelet alpha granule. Part of heterochromatin; insulin-like growth factor binary complex; and insulin-like growth factor ternary complex. Used to study impotence. Biomarker of congenital diaphragmatic hernia; impotence; and obesity. Human ortholog(s) of this gene implicated in several diseases, including Alzheimer's disease; Turner syndrome; diabetes mellitus (multiple); prostate cancer; and transitional cell carcinoma. Orthologous to human IGFBP3 (insulin like growth factor binding protein 3); PARTICIPATES IN insulin-like growth factor signaling pathway; p53 signaling pathway; INTERACTS WITH (+)-pilocarpine; (R)-lipoic acid; 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: IBP-3; IGF-binding protein 3; IGF-BP3; IGFBP-3; Insulin-like growth factor-binding protein (IGF-BP3); insulin-like growth factor-binding protein 3; MGC156773
RGD Orthologs
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Candidate Gene For: Niddm37
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.21482,056,347 - 82,064,083 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1482,056,347 - 82,064,083 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1486,457,400 - 86,465,160 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01487,697,249 - 87,705,011 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01484,145,931 - 84,153,669 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01487,457,647 - 87,465,374 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1487,457,647 - 87,465,374 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01481,091,987 - 81,099,675 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41487,959,153 - 87,967,085 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11487,978,297 - 87,986,223 (-)NCBI
Celera1481,130,767 - 81,138,473 (-)NCBICelera
RH 3.4 Map14598.5RGD
Cytogenetic Map14q21NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Disease Annotations     Click to see Annotation Detail View
acoustic neuroma  (ISO)
Acute-Phase Reaction  (ISO)
Alzheimer's disease  (ISO)
ankylosing spondylitis  (ISO)
arteriosclerosis  (ISO)
autistic disorder  (ISO)
Barrett's esophagus  (ISO)
beta thalassemia  (ISO)
Brain Hypoxia-Ischemia  (IEP)
breast cancer  (ISO)
Burns  (IEP)
cervix uteri carcinoma in situ  (ISO)
Closed Head Injuries  (ISO)
Colorectal Neoplasms  (ISO)
Congenital Adrenal Hyperplasia due to 21 Hydroxylase Deficiency  (ISO)
congenital diaphragmatic hernia  (IEP)
congenital disorder of glycosylation Ia  (ISO)
Coronary Disease  (ISO)
cystic fibrosis  (ISO)
Down syndrome  (ISO)
Dwarfism  (ISO)
Endometrial Neoplasms  (ISO)
Endometrioid Carcinomas  (ISO)
Endotoxemia  (IEP)
epidermolysis bullosa dystrophica  (ISO)
Experimental Arthritis  (IEP)
Experimental Diabetes Mellitus  (IEP,IMP,ISO)
Experimental Liver Cirrhosis  (ISO)
Fetal Growth Retardation  (IEP,ISO)
Fetal Macrosomia  (ISO)
genetic disease  (ISO)
high grade glioma  (ISO)
ichthyosis  (ISO)
impotence  (IEP,IMP)
inflammatory bowel disease  (ISO)
Insulin Resistance  (ISO)
Malocclusion  (IEP)
McCune Albright syndrome  (ISO)
Metabolic Bone Diseases  (ISO)
myeloid leukemia  (ISO)
Myocardial Ischemia  (ISO)
obesity  (IEP)
ornithine carbamoyltransferase deficiency  (ISO)
osteoarthritis  (ISO)
osteoporosis  (ISO)
Ovarian Neoplasms  (ISO)
pleomorphic xanthoastrocytoma  (ISO)
primary progressive multiple sclerosis  (ISO)
prostate cancer  (ISO)
Prostatic Neoplasms  (ISO)
pulmonary fibrosis  (ISO)
renal cell carcinoma  (ISO)
retinopathy of prematurity  (ISO)
rheumatoid arthritis  (ISO)
Spinal Fractures  (ISO)
Spontaneous Abortions  (ISO)
stomach cancer  (ISO)
Stomach Neoplasms  (ISO)
systemic scleroderma  (ISO)
tonsillitis  (ISO)
transitional cell carcinoma  (ISO)
Turner syndrome  (ISO)
type 1 diabetes mellitus  (ISO)
type 2 diabetes mellitus  (ISO)
urinary bladder cancer  (ISO)
Uterine Cervical Neoplasms  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-pilocarpine  (EXP)
(R)-lipoic acid  (EXP)
1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane  (EXP)
1,2-dichloroethane  (ISO)
1,2-dimethylhydrazine  (ISO)
1-naphthyl isothiocyanate  (EXP,ISO)
17alpha-ethynylestradiol  (EXP,ISO)
17beta-estradiol  (EXP,ISO)
17beta-estradiol 3-benzoate  (EXP)
17beta-hydroxy-17-methylestra-4,9,11-trien-3-one  (ISO)
17beta-hydroxy-5alpha-androstan-3-one  (ISO)
2,2',4,4',5,5'-hexachlorobiphenyl  (ISO)
2,2',4,4'-Tetrabromodiphenyl ether  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4-dibromophenyl 2,4,5-tribromophenyl ether  (ISO)
2,5-hexanedione  (EXP)
2-amino-2-deoxy-D-glucopyranose  (EXP)
2-hydroxypropanoic acid  (ISO)
2-methoxyethanol  (EXP)
2-methylcholine  (ISO)
2-nitrofluorene  (EXP)
2-nitrotoluene  (EXP)
3,3',4,4',5-pentachlorobiphenyl  (EXP,ISO)
3,3',4,4'-tetrachlorobiphenyl  (ISO)
3,3',5,5'-tetrabromobisphenol A  (ISO)
3,4-dichloroaniline  (ISO)
3-chloropropane-1,2-diol  (EXP)
3-isobutyl-1-methyl-7H-xanthine  (ISO)
3H-1,2-dithiole-3-thione  (EXP)
4,4'-diaminodiphenylmethane  (EXP,ISO)
4,4'-sulfonyldiphenol  (ISO)
4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one  (EXP)
4-hydroxyphenyl retinamide  (ISO)
5-aza-2'-deoxycytidine  (ISO)
6-propyl-2-thiouracil  (EXP)
9-cis-retinoic acid  (ISO)
acetamide  (EXP)
afimoxifene  (ISO)
aflatoxin B1  (EXP,ISO)
aldehydo-D-glucosamine  (EXP)
all-trans-4-oxoretinoic acid  (ISO)
all-trans-retinoic acid  (EXP,ISO)
aluminium sulfate (anhydrous)  (ISO)
ammonium chloride  (EXP)
ampicillin  (ISO)
Archazolid B  (ISO)
aristolochic acid A  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenite(3-)  (ISO)
arsenous acid  (ISO)
azathioprine  (ISO)
benzene  (EXP)
benzo[a]pyrene  (ISO)
benzo[b]fluoranthene  (ISO)
beta-D-glucosamine  (EXP)
beta-naphthoflavone  (ISO)
bexarotene  (EXP)
bicalutamide  (EXP,ISO)
bilirubin IXalpha  (ISO)
bis(2-chloroethyl) sulfide  (ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
bromochloroacetic acid  (EXP)
bucladesine  (ISO)
buta-1,3-diene  (ISO)
butanal  (ISO)
C60 fullerene  (EXP)
cadmium atom  (ISO)
cadmium dichloride  (ISO)
calciol  (ISO)
calcitriol  (ISO)
captan  (ISO)
carbamazepine  (ISO)
carbon nanotube  (ISO)
carmustine  (EXP)
chloroethene  (ISO)
chlorohydrocarbon  (ISO)
chloroprene  (ISO)
cholesterol  (EXP)
cisplatin  (ISO)
clobetasol  (ISO)
clofibric acid  (EXP)
cobalt dichloride  (ISO)
copper atom  (EXP,ISO)
copper(0)  (EXP,ISO)
curcumin  (EXP,ISO)
cyclophosphamide  (EXP,ISO)
cyclosporin A  (ISO)
cytarabine  (ISO)
decabromodiphenyl ether  (ISO)
dehydroepiandrosterone  (ISO)
deoxynivalenol  (ISO)
dexamethasone  (EXP,ISO)
diallyl trisulfide  (ISO)
diarsenic trioxide  (ISO)
dichlorine  (EXP)
diclofenac  (ISO)
Didecyldimethylammonium  (ISO)
diethylstilbestrol  (EXP,ISO)
dioxygen  (EXP,ISO)
diquat  (ISO)
diuron  (EXP,ISO)
dorsomorphin  (ISO)
doxorubicin  (ISO)
elemental selenium  (ISO)
entinostat  (ISO)
ethanol  (ISO)
fenamidone  (ISO)
flavonoids  (EXP)
flutamide  (EXP,ISO)
folic acid  (ISO)
folpet  (ISO)
fonofos  (ISO)
fructose  (EXP)
fulvestrant  (ISO)
gadolinium trichloride  (EXP)
gemcitabine  (ISO)
genistein  (ISO)
glafenine  (EXP)
glutathione  (ISO)
glycidol  (EXP)
graphene oxide  (ISO)
hexachlorobenzene  (ISO)
hydroquinone  (ISO)
indometacin  (ISO)
iron atom  (EXP,ISO)
iron dichloride  (ISO)
iron(0)  (EXP,ISO)
isoflavones  (ISO)
isoprenaline  (EXP)
isotretinoin  (ISO)
ivermectin  (EXP)
ketamine  (EXP)
leflunomide  (ISO)
levonorgestrel  (ISO)
lipoic acid  (EXP)
lipopolysaccharide  (EXP,ISO)
LY294002  (ISO)
medroxyprogesterone acetate  (ISO)
mercury dibromide  (ISO)
methapyrilene  (EXP)
methidathion  (ISO)
methimazole  (EXP)
methotrexate  (EXP,ISO)
methoxyacetic acid  (ISO)
methylmercury chloride  (ISO)
methylmercury(1+)  (EXP)
mifepristone  (ISO)
mitoxantrone  (ISO)
mono(2-ethylhexyl) phthalate  (ISO)
Monobutylphthalate  (ISO)
monosodium L-glutamate  (ISO)
Muraglitazar  (EXP)
N-methyl-4-phenylpyridinium  (ISO)
N-nitrosodiethylamine  (EXP,ISO)
N-nitrosodimethylamine  (EXP)
N-Nitrosopyrrolidine  (ISO)
naphthalene  (EXP,ISO)
nefazodone  (EXP)
nickel atom  (ISO)
nickel dichloride  (ISO)
nickel subsulfide  (ISO)
nimesulide  (EXP)
nitrofen  (EXP)
nonanedioic acid  (ISO)
oxaliplatin  (EXP,ISO)
ozone  (EXP,ISO)
p-chloromercuribenzoic acid  (ISO)
p-toluidine  (EXP)
panobinostat  (ISO)
paracetamol  (ISO)
parathion  (ISO)
PD 0325901  (ISO)
pentanal  (ISO)
perfluorononanoic acid  (ISO)
perfluorooctane-1-sulfonic acid  (EXP,ISO)
perfluorooctanoic acid  (EXP,ISO)
permethrin  (EXP)
phenobarbital  (EXP,ISO)
phorbol 13-acetate 12-myristate  (ISO)
piperonyl butoxide  (EXP)
pirinixic acid  (EXP,ISO)
poly(I:C)  (ISO)
potassium dichromate  (ISO)
progesterone  (EXP,ISO)
propanal  (ISO)
propiconazole  (ISO)
quercetin  (EXP,ISO)
quinolin-8-ol  (ISO)
rac-lactic acid  (ISO)
raloxifene  (ISO)
resveratrol  (ISO)
rifampicin  (ISO)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
SB 431542  (ISO)
selenium atom  (ISO)
serpentine asbestos  (ISO)
silicon dioxide  (ISO)
silver atom  (ISO)
silver(0)  (ISO)
sirolimus  (ISO)
sirtinol  (ISO)
sodium arsenate  (ISO)
sodium arsenite  (ISO)
sodium dichromate  (ISO)
Soman  (EXP)
streptozocin  (ISO)
succimer  (ISO)
sulfasalazine  (EXP)
sunitinib  (ISO)
tamibarotene  (ISO)
tamoxifen  (EXP,ISO)
taurine  (ISO)
temozolomide  (ISO)
terbufos  (ISO)
tert-butyl hydroperoxide  (ISO)
testosterone  (EXP,ISO)
testosterone undecanoate  (ISO)
Tetrachlorobisphenol A  (ISO)
tetrachloromethane  (ISO)
tetracycline  (ISO)
thalidomide  (ISO)
thapsigargin  (ISO)
thioacetamide  (EXP)
tioguanine  (EXP)
titanium dioxide  (ISO)
topotecan  (EXP,ISO)
tremolite asbestos  (ISO)
trichloroethene  (EXP)
trichostatin A  (ISO)
triclosan  (ISO)
trimellitic anhydride  (ISO)
triphenyl phosphate  (EXP)
tris(2-butoxyethyl) phosphate  (ISO)
troglitazone  (ISO)
tunicamycin  (ISO)
urethane  (ISO)
valdecoxib  (EXP)
valproic acid  (ISO)
vandetanib  (ISO)
vinclozolin  (EXP)
zearalenone  (ISO)
zebularine  (ISO)
zinc atom  (EXP,ISO)
zinc(0)  (EXP,ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process

Cellular Component

Molecular Function

Molecular Pathway Annotations     Click to see Annotation Detail View

References - curated
# Reference Title Reference Citation
1. Growth hormone action on proliferation and differentiation of cerebral cortical cells from fetal rat. Ajo R, etal., Endocrinology 2003 Mar;144(3):1086-97.
2. Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome. Akintoye SO, etal., J Clin Endocrinol Metab. 2006 Aug;91(8):2960-6. Epub 2006 May 23.
3. ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. Arao T, etal., Int J Cancer. 2006 Jan 15;118(2):483-9. doi: 10.1002/ijc.21340.
4. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Asthana S, etal., Psychoneuroendocrinology. 1999 Aug;24(6):657-77.
5. Reduction of IGF-binding protein-3 as a potential marker of intra-uterine growth restriction. Baker Méio MD, etal., J Perinat Med. 2009;37(6):689-93. doi: 10.1515/JPM.2009.122.
6. Circulating levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in patients with severe head injury. Beeton CA, etal., J Bone Joint Surg Br. 2002 Apr;84(3):434-9.
7. IGF-I and IGFBP-3 transport in the rat heart. Boes M, etal., Am J Physiol Endocrinol Metab 2003 Jan;284(1):E237-9.
8. The interactive effect of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on rhGH responsiveness and treatment outcomes in patients with Turner syndrome. Braz AF, etal., J Clin Endocrinol Metab. 2012 Apr;97(4):E671-7. doi: 10.1210/jc.2011-2521. Epub 2012 Jan 25.
9. Gene expression patterns of insulin-like growth factor 1, insulin-like growth factor 2 and insulin-like growth factor binding protein 3 in human placenta from pregnancies with intrauterine growth restriction. Börzsönyi B, etal., J Perinat Med. 2011 Nov;39(6):701-7. doi: 10.1515/JPM.2011.090. Epub 2011 Aug 8.
10. Inverse correlation between serum free IGF-I and IGFBP-3 levels and blood pressure in patients affected with type 1 diabetes. Capoluongo E, etal., Cytokine. 2006 Jun;34(5-6):303-11. Epub 2006 Aug 2.
11. Megakaryocytes endocytose insulin-like growth factor (IGF) I and IGF-binding protein-3: a novel mechanism directing them into alpha granules of platelets. Chan K and Spencer EM, Endocrinology. 1998 Feb;139(2):559-65.
12. Insulin-like growth factor binding protein-3 in the detection of fetal Down syndrome pregnancies. Chu DC, etal., Obstet Gynecol. 1998 Feb;91(2):192-5.
13. Over expression of insulin-like growth factor binding protein 3 in clear cell renal cell carcinoma. Chuang ST, etal., J Urol. 2008 Feb;179(2):445-9.
14. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Clemmons DR, etal., Growth Horm IGF Res. 2005 Aug;15(4):265-74.
15. Short stature in children with sickle cell anemia correlates with alterations in the IGF-I axis. Collett-Solberg PF, etal., J Pediatr Endocrinol Metab. 2007 Feb;20(2):211-8.
16. Roles of insulin-like growth factor (IGF) binding proteins in regulating IGF actions. Duan C and Xu Q, Gen Comp Endocrinol. 2005 May 15;142(1-2):44-52. Epub 2005 Feb 5.
17. Effect of growth hormone on small intestinal homeostasis relation to cellular mediators IGF-I and IGFBP-3. Ersoy B, etal., World J Gastroenterol. 2009 Nov 21;15(43):5418-24.
18. Effects of Adenotonsillectomy on Serum Levels of IGF-1 and IGFBP-3 and Growth Indices in Children with Adenotonsillar Hypertrophy or Recurrent Tonsillitis. Farmarzi M, etal., Iran J Otorhinolaryngol. 2016 Sep;28(88):329-335.
19. Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid-labile subunit with coronary heart disease. Fischer F, etal., Clin Endocrinol (Oxf). 2004 Nov;61(5):595-602.
20. Developmental changes in serum levels of free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit in rats. Frystyk J, etal., Endocrinology. 1998 Oct;139(10):4286-92.
21. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
22. Differential transcriptome analysis of intraarticular lesional vs intact cartilage reveals new candidate genes in osteoarthritis pathophysiology. Geyer M, etal., Osteoarthritis Cartilage. 2009 Mar;17(3):328-35. doi: 10.1016/j.joca.2008.07.010. Epub 2008 Sep 4.
23. Insulin-like growth factor binding protein-3 in preterm infants with retinopathy of prematurity. Gharehbaghi MM, etal., Indian J Ophthalmol. 2012 Nov-Dec;60(6):527-30. doi: 10.4103/0301-4738.103782.
24. Estradiol and triiodothyronine increase production of insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) by GH4C1 rat pituitary tumor cells. Gilchrist CA, etal., Mol Cell Endocrinol 1995 Oct 30;114(1-2):147-56.
25. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
26. Growth factors and glucose homeostasis in diabetic rats: effects of exercise training. Gomes RJ, etal., Cell Biochem Funct. 2009 Apr 20.
27. Insulin-like growth factor binding protein-3 mediates serum starvation- and doxorubicin-induced apoptosis in H9c2 cardiac cells. Granata R, etal., J Endocrinol Invest. 2003 Dec;26(12):1231-41.
28. Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids. Gravholt CH, etal., Am J Physiol Endocrinol Metab. 2001 Feb;280(2):E308-14.
29. The GH-IGF-IGFBP axis is changed in Turner syndrome: partial normalization by HRT. Gravholt CH, etal., Growth Horm IGF Res. 2006 Oct-Dec;16(5-6):332-9. Epub 2006 Oct 25.
30. Changes of insulin-mediated protein kinases phosphorylation and the expression of IGFBP-3 in skeletal muscle of streptozotocin-diabetic mice. Grzelkowska-Kowalczyk K and Wieteska W, Pol J Vet Sci. 2005;8(3):231-40.
31. A graded model of dietary zinc deficiency: effects on growth, insulin-like growth factor-I, and the glucose/insulin axis in weanling rats. Hall AG, etal., J Pediatr Gastroenterol Nutr. 2005 Jul;41(1):72-80.
32. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis. Hamaguchi Y, etal., J Rheumatol. 2008 Dec;35(12):2363-71. doi: 10.3899/jrheum.080340. Epub 2008 Nov 1.
33. Binding sites and binding properties of binary and ternary complexes of insulin-like growth factor-II (IGF-II), IGF-binding protein-3, and acid-labile subunit. Hashimoto R, etal., J Biol Chem. 1997 Oct 31;272(44):27936-42.
34. IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Hernandez W, etal., Carcinogenesis. 2007 Oct;28(10):2154-9. Epub 2007 Aug 27.
35. EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder. Hinz S, etal., Tumour Biol. 2007;28(3):151-7. Epub 2007 Jun 1.
36. [Study on intermittent hypoxia in children sleep apnea hypopnea syndrome model and insulin-like growth factor-1 and insulin-like growth factor binding protein-3 levels in serum]. Hou J, etal., Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012 Mar;47(3):218-22.
37. Grade-specific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites. Hoyo C, etal., J Natl Med Assoc. 2007 Jul;99(7):718-22.
38. Co-administration of finasteride and the pure anti-oestrogen ICI 182,780 act synergistically in modulating the IGF system in rat prostate. Huynh H, etal., J Endocrinol 2001 Oct;171(1):109-18.
39. Effect of inducible nitric oxide synthase inhibition by aminoguanidine on insulin-like growth factor binding protein-3 in adjuvant-induced arthritic rats. Ibanez de Caceres I, etal., Eur J Pharmacol. 2003 Nov 28;481(2-3):293-9.
40. Insulin-like growth factor I in combination with insulin-like growth factor binding protein 3 affects the hepatic acute phase response and hepatic morphology in thermally injured rats. Jeschke MG, etal., Ann Surg. 2000 Mar;231(3):408-16.
41. Systemic propranolol reduces b-wave amplitude in the ERG and increases IGF-1 receptor phosphorylation in rat retina. Jiang Y and Steinle JJ, Invest Ophthalmol Vis Sci. 2010 May;51(5):2730-5. doi: 10.1167/iovs.09-4779. Epub 2009 Dec 30.
42. Reduced serum levels of the growth hormone-dependent insulin-like growth factor binding protein and a negative bone balance at the level of individual remodeling units in idiopathic osteoporosis in men. Johansson AG, etal., J Clin Endocrinol Metab. 1997 Sep;82(9):2795-8.
43. Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. Johansson P, etal., Psychoneuroendocrinology. 2013 Sep;38(9):1729-37. doi: 10.1016/j.psyneuen.2013.02.006. Epub 2013 Mar 6.
44. Serum IGF-binding protein-6 and prostate specific antigen in breast cancer. Kaulsay KK, etal., Eur J Endocrinol. 1999 Feb;140(2):164-8.
45. Circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 are associated with early carotid atherosclerosis. Kawachi S, etal., Arterioscler Thromb Vasc Biol. 2005 Mar;25(3):617-21. Epub 2004 Dec 29.
46. Insulin-like growth factor binding protein-3 induces insulin resistance in adipocytes in vitro and in rats in vivo. Kim HS, etal., Pediatr Res. 2007 Feb;61(2):159-64.
47. Regulation of replicative senescence by insulin-like growth factor-binding protein 3 in human umbilical vein endothelial cells. Kim KS, etal., Aging Cell. 2007 Aug;6(4):535-45.
48. Insulin-like growth factor binding protein 3 in inflammatory bowel disease. Kirman I, etal., Dig Dis Sci. 2005 Apr;50(4):780-4.
49. Serum insulin-like growth factor-I (IGF-I) IGF binding protein-3 (IGFBP-3) and leptin levels are related to abdominal aortic intima-media thickness in macrosomic newborns. Koklu E, etal., Growth Horm IGF Res. 2007 Feb;17(1):26-32. Epub 2006 Nov 20.
50. Serum insulin-like growth factor-I (IGF-I), IGF-binding protein-3, and growth hormone levels in collodion babies: a case-control study. Kurtoglu S, etal., J Pediatr Endocrinol Metab. 2008 Jul;21(7):689-94.
51. High-density rat radiation hybrid maps containing over 24,000 SSLPs, genes, and ESTs provide a direct link to the rat genome sequence. Kwitek AE, etal., Genome Res. 2004 Apr;14(4):750-7
52. Expression of insulin-like growth factor binding proteins in the rat kidney: effects of long-term diabetes. Landau D, etal., Endocrinology. 1995 May;136(5):1835-42. doi: 10.1210/endo.136.5.7536658.
53. Acute response of IGF-I and IGF binding proteins induced by thermal injury. Lang CH, etal., Am J Physiol Endocrinol Metab. 2000 Jun;278(6):E1087-96.
54. Perinatal hypoxia-ischemia decreased neuronal but increased cerebral vascular endothelial IGFBP3 expression. Lee WH, etal., Endocrine. 1999 Oct;11(2):181-8.
55. No association between genetic polymorphisms in IGF-I and IGFBP-3 and prostate cancer. Li L, etal., Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):497-8.
56. Serum growth hormone (GH) binding protein, IGF-I and IGFBP-3 in patients with beta-thalassaemia major and the effect of GH treatment. Low LC, etal., Clin Endocrinol (Oxf). 1998 May;48(5):641-6.
57. [Effects of L-arginine on the expression of insulin-like growth factors and insulin-like growth factor binding protein 3 in rats with intrauterine growth retardation]. Lu Y, etal., Zhongguo Dang Dai Er Ke Za Zhi. 2006 Aug;8(4):319-22.
58. Reduced expression of insulin-like growth factor-binding protein-3 (IGFBP-3) in Squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa. Mallipeddi R, etal., J Invest Dermatol. 2004 May;122(5):1302-9.
59. Cyclooxygenase-2 activation by endotoxin mediates the decrease in IGF1, but not in IGFBP3, [corrected] gene expression in the liver. Martin AI, etal., J Endocrinol. 2008 Aug;198(2):385-94. doi: 10.1677/JOE-08-0205. Epub 2008 May 20.
60. Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer. Mathur SP, etal., Gynecol Oncol. 2003 Dec;91(3):486-93.
61. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
62. IGF system in children with congenital disorders of glycosylation. Miller BS, etal., Clin Endocrinol (Oxf). 2009 Jun;70(6):892-7. doi: 10.1111/j.1365-2265.2009.03531.x. Epub 2009 Jan 22.
63. Amniotic fluid insulin-like growth factor binding protein 3 concentration as early indicator of fetal growth restriction. Murisier-Petetin G, etal., Eur J Obstet Gynecol Reprod Biol. 2009 May;144(1):15-20. doi: 10.1016/j.ejogrb.2009.01.004. Epub 2009 Feb 13.
64. Effects of arginine treatment on nutrition, growth and urea cycle function in seven Japanese boys with late-onset ornithine transcarbamylase deficiency. Nagasaka H, etal., Eur J Pediatr. 2006 Sep;165(9):618-24. Epub 2006 May 16.
65. The effects of recombinant human insulin-like growth factor (rhIGF)-1 and rhIGF-1/IGF binding protein-3 administration on rat osteopenia induced by ovariectomy with concomitant bilateral sciatic neurectomy. Narusawa K, etal., J Bone Miner Res. 1995 Dec;10(12):1853-64.
66. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
67. Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Oh JC, etal., Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):748-52.
68. Relation between serum Insulin-like growth factor-I and insulin-like growth factor-binding protein-3 levels, clinical status and growth parameters in prepubertal cystic fibrosis patients. Ozen M, etal., Pediatr Int. 2004 Aug;46(4):429-35.
69. Role of IGFBP-3 in the regulation of beta-cell mass during obesity: adipose tissue/beta-cell cross talk. Palau N, etal., Endocrinology. 2012 Jan;153(1):177-87. doi: 10.1210/en.2011-0181. Epub 2011 Nov 8.
70. Growth hormone-binding protein is directly and IGFBP-3 is inversely associated with risk of female breast cancer. Pazaitou-Panayiotou K, etal., Eur J Endocrinol. 2007 Feb;156(2):187-94.
71. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Pilewski JM, etal., Am J Pathol. 2005 Feb;166(2):399-407.
72. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
73. Hepatic insulin-like growth factor-I binding protein 3 gene expression in rats with endotoxic shock: the role of glucocorticoids. Priego T, etal., Ann N Y Acad Sci 2002 Nov;973:88-90.
74. Dexamethasone administration attenuates the inhibitory effect of lipopolysaccharide on IGF-I and IGF-binding protein-3 in adult rats. Priego T, etal., J Endocrinol. 2005 Jun;185(3):467-76.
75. Higher expression of mRNA and protein of insulin-like growth factor binding protein-3 in old rat penile tissues: implications for erectile dysfunction. Pu XY, etal., J Sex Med. 2011 Aug;8(8):2181-90. doi: 10.1111/j.1743-6109.2011.02318.x. Epub 2011 May 19.
76. shRNA constructs targeting IGFBP-3 alleviate age related erectile dysfunction in the rat. Pu XY, etal., J Urol. 2014 Sep;192(3):990-6. doi: 10.1016/j.juro.2014.02.042. Epub 2014 Feb 24.
77. Effects of early nutrition intervention on IGF1, IGFBP3, intestinal development, and catch-up growth of intrauterine growth retardation rats. Qiu XS, etal., Chin Med Sci J. 2004 Sep;19(3):189-92.
78. Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Ren Z, etal., Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1290-5.
79. GOA pipeline RGD automated data pipeline
80. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
81. Concentrations of IGF-I and IGFBP-3 and brain tumor risk in the European Prospective Investigation into Cancer and Nutrition. Rohrmann S, etal., Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2174-82. doi: 10.1158/1055-9965.EPI-11-0179. Epub 2011 Jul 25.
82. Downregulation of insulin-like growth factor binding protein 3 and 5 in nitrofen-induced pulmonary hypoplasia. Ruttenstock E, etal., Pediatr Surg Int. 2010 Jan;26(1):59-63. doi: 10.1007/s00383-009-2509-5.
83. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes. Saukkonen T, etal., J Clin Endocrinol Metab. 2004 Sep;89(9):4634-41.
84. Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Schernhammer ES, etal., Int J Cancer. 2003 Oct 20;107(1):60-4.
85. Insulin-like growth factor system gene expression in cervical scrapes from women with squamous intraepithelial lesions and cervical cancer. Serrano ML, etal., Growth Horm IGF Res. 2007 Dec;17(6):492-9. Epub 2007 Aug 20.
86. Insulin-like growth factor binding protein-3 is a novel mediator of apoptosis in insulin-secreting cells. Shim ML, etal., Growth Horm IGF Res. 2004 Jun;14(3):216-25.
87. Longitudinal study of insulin-like growth factor, insulin-like growth factor binding protein-3, and their polymorphisms: risk of neoplastic progression in Barrett's esophagus. Siahpush SH, etal., Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2387-95.
88. Localization of increased insulin-like growth factor binding protein-3 in diabetic rat penis: implications for erectile dysfunction. Soh J, etal., Urology. 2007 Nov;70(5):1019-23.
89. Skeletal muscle IGF-binding protein-3 and -5 expressions are age, muscle, and load dependent. Spangenburg EE, etal., Am J Physiol Endocrinol Metab 2003 Feb;284(2):E340-50.
90. [Methylation of insulin-like growth factor binding protein 3 gene in neonates with intrauterine growth restriction]. Su AL, etal., Zhongguo Dang Dai Er Ke Za Zhi. 2011 Sep;13(9):700-3.
91. Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. Sugimoto T, etal., J Bone Miner Res. 1997 Aug;12(8):1272-9.
92. Amyloid beta-mediated epigenetic alteration of insulin-like growth factor binding protein 3 controls cell survival in Alzheimer's disease. Sung HY, etal., PLoS One. 2014 Jun 25;9(6):e99047. doi: 10.1371/journal.pone.0099047. eCollection 2014.
93. Tentative Sequence Identification Numbers Tentative Sequence Data IDs. TIGR Gene Index, Rat Data
94. Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma. Torng PL, etal., Oncogene. 2008 Apr 3;27(15):2137-47. Epub 2007 Oct 22.
95. Insulin-like growth factor-I and insulin-like growth factor binding protein-3 serum levels in ankylosing spondylitis. Toussirot E, etal., Br J Rheumatol. 1998 Nov;37(11):1172-6.
96. TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model. Ulmer A, etal., Klin Padiatr. 2013 May;225(3):120-6. doi: 10.1055/s-0033-1343483. Epub 2013 May 28.
97. Insulin-like growth factor binding protein-3 mediates cytokine-induced mesangial cell apoptosis. Vasylyeva TL, etal., Growth Horm IGF Res. 2005 Jun;15(3):207-14. Epub 2005 Mar 23.
98. Growth hormone gene expression and secretion in aging rats is age dependent and not age-associated weight increase related. Velasco B, etal., Endocrinology. 1998 Mar;139(3):1314-20. doi: 10.1210/endo.139.3.5779.
99. Insulin and insulin-like growth factor-I regulate hepatic insulin-like growth factor binding protein-3 by different mechanisms. Villafuerte BC, etal., Mol Endocrinol. 1996 Jun;10(6):622-30.
100. IGF-I-IGFBP-3-acid-labile subunit (ALS) complex in children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH). Völkl TM, etal., Growth Horm IGF Res. 2011 Aug;21(4):191-8. doi: 10.1016/j.ghir.2011.05.001. Epub 2011 Jun 1.
101. The GH1/IGF-1 axis polymorphisms and their impact on breast cancer development. Wagner K, etal., Breast Cancer Res Treat. 2007 Sep;104(3):233-48. Epub 2006 Nov 2.
102. Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Walker G, etal., Clin Cancer Res. 2007 Mar 1;13(5):1438-44.
103. Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis. Wilczak N, etal., Mult Scler. 2005 Feb;11(1):13-5.
104. Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Wiley A, etal., Int J Gynecol Cancer. 2006 Jan-Feb;16(1):210-8.
105. Differential expression of IGF1, IGFR1 and IGFBP3 in mandibular condylar cartilage between male and female rats applied with malocclusion. Yu S, etal., J Oral Rehabil. 2012 Oct;39(10):727-36. doi: 10.1111/j.1365-2842.2012.02332.x. Epub 2012 Jul 3.
106. Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. Zhao H, etal., J Urol. 2003 Feb;169(2):714-7.
107. Short hairpin ribonucleic acid constructs targeting insulin-like growth factor binding protein-3 rehabilitated decreased testosterone concentrations in diabetic rats. Zhou ZY, etal., Med Sci Monit. 2015 Jan 8;21:94-9. doi: 10.12659/MSM.891382.
Additional References at PubMed
PMID:1689154   PMID:2443135   PMID:2480123   PMID:2480787   PMID:3190697   PMID:7510770   PMID:7530650   PMID:7679139   PMID:9497324   PMID:10766744   PMID:11940579   PMID:11971816  
PMID:12477932   PMID:12508914   PMID:12581876   PMID:12599210   PMID:13129855   PMID:15845624   PMID:15956343   PMID:16037377   PMID:16055936   PMID:16098781   PMID:16311053   PMID:16340176  
PMID:16675541   PMID:17003344   PMID:17119061   PMID:17434920   PMID:17591901   PMID:19236847   PMID:19258508   PMID:19887447   PMID:20498031   PMID:20519361   PMID:22008548   PMID:22792172  
PMID:23376485   PMID:24006456   PMID:25879169   PMID:27439004   PMID:30659610   PMID:34284540   PMID:35154570  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.21482,056,347 - 82,064,083 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1482,056,347 - 82,064,083 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1486,457,400 - 86,465,160 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01487,697,249 - 87,705,011 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01484,145,931 - 84,153,669 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01487,457,647 - 87,465,374 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1487,457,647 - 87,465,374 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01481,091,987 - 81,099,675 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41487,959,153 - 87,967,085 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11487,978,297 - 87,986,223 (-)NCBI
Celera1481,130,767 - 81,138,473 (-)NCBICelera
RH 3.4 Map14598.5RGD
Cytogenetic Map14q21NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh38745,912,245 - 45,921,272 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl745,912,245 - 45,921,874 (-)EnsemblGRCh38hg38GRCh38
GRCh37745,951,844 - 45,960,871 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 36745,918,369 - 45,927,396 (-)NCBINCBI36Build 36hg18NCBI36
Build 34745,725,189 - 45,734,057NCBI
Celera746,050,761 - 46,059,785 (-)NCBICelera
Cytogenetic Map7p12.3NCBI
HuRef745,836,799 - 45,845,824 (-)NCBIHuRef
CHM1_1745,956,047 - 45,965,072 (-)NCBICHM1_1
T2T-CHM13v2.0746,073,961 - 46,082,986 (-)NCBIT2T-CHM13v2.0
CRA_TCAGchr7v2745,991,173 - 46,000,198 (-)NCBI
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm39117,156,086 - 7,165,498 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl117,156,086 - 7,163,923 (-)EnsemblGRCm39 Ensembl
GRCm38117,206,086 - 7,215,498 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl117,206,086 - 7,213,923 (-)EnsemblGRCm38mm10GRCm38
MGSCv37117,106,089 - 7,113,926 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36117,108,384 - 7,113,834 (-)NCBIMGSCv36mm8
Celera117,681,286 - 7,689,161 (-)NCBICelera
Cytogenetic Map11A1NCBI
cM Map114.75NCBI
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
ChiLan1.0 EnsemblNW_0049554566,795,604 - 6,800,845 (+)EnsemblChiLan1.0
ChiLan1.0NW_0049554566,795,560 - 6,802,147 (+)NCBIChiLan1.0ChiLan1.0
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
NHGRI_mPanPan1799,122,231 - 99,131,164 (-)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v0746,564,234 - 46,573,145 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.1746,681,856 - 46,690,240 (-)NCBIpanpan1.1PanPan1.1panPan2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.1161,021,855 - 1,027,604 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl161,021,972 - 1,026,392 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha161,797,939 - 1,804,689 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.0161,008,571 - 1,015,327 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl161,008,253 - 1,015,330 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.116999,220 - 1,005,969 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.016934,846 - 941,592 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.016233,123 - 239,875 (-)NCBIUU_Cfam_GSD_1.0
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
HiC_Itri_2NW_024405118101,299,235 - 101,306,540 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_00493647820,510,137 - 20,518,306 (-)EnsemblSpeTri2.0SpeTri2.0 Ensembl
SpeTri2.0NW_00493647820,511,490 - 20,518,251 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
Sscrofa11.1 Ensembl1850,003,022 - 50,010,690 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11850,002,921 - 50,009,425 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21854,851,168 - 54,855,699 (+)NCBISscrofa10.2Sscrofa10.2susScr3
Pig Cytomap18q24NCBI
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
ChlSab1.12112,905,309 - 12,914,199 (+)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl2112,905,280 - 12,914,205 (+)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_0236660629,622,694 - 9,631,602 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
HetGla_female_1.0 EnsemblNW_0046247406,877,348 - 6,886,512 (+)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046247406,878,818 - 6,886,512 (+)NCBIHetGla_female_1.0HetGla 1.0hetGla2


Variants in Igfbp3
36 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:649
Count of miRNA genes:284
Interacting mature miRNAs:345
Prediction methods:Microtar, Miranda
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
631839Niddm37Non-insulin dependent diabetes mellitus QTL 373.37blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)141103062295876975Rat
2313048Bss84Bone structure and strength QTL 843.10.0001tibia strength trait (VT:1000284)tibia total energy absorbed before break (CMO:0001736)143766971982669719Rat
2313084Bss83Bone structure and strength QTL 832.90.0001tibia size trait (VT:0100001)tibia midshaft endosteal cross-sectional area (CMO:0001716)143766971982669719Rat
2313089Bss81Bone structure and strength QTL 813.40.0001body length (VT:0001256)body length, nose to rump (CMO:0000079)143766971982669719Rat
2313100Bss82Bone structure and strength QTL 8230.0001tibia size trait (VT:0100001)tibia midshaft cross-sectional area (CMO:0001717)143766971982669719Rat
738037Hcas6Hepatocarcinoma susceptibility QTL 62.93liver integrity trait (VT:0010547)liver nonremodeling tumorous lesion volume to total liver volume ratio (CMO:0001464)143905723783368335Rat
631523Pia13Pristane induced arthritis QTL 133.3joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)144079346098037301Rat
1300136Rf22Renal function QTL 223.9renal blood flow trait (VT:2000006)absolute change in renal vascular resistance (CMO:0001900)144226252995023211Rat
1549834Scl45Serum cholesterol level QTL 455.8blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)145002321195023211Rat
2300197Scl59Serum cholesterol level QTL 59blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)1455147478100147478Rat
9590294Uminl4Urine mineral level QTL 45.660.001urine mineral amount (VT:0015086)urine electrolyte level (CMO:0000593)1455624247100624247Rat
9589034Epfw11Epididymal fat weight QTL 1160.001epididymal fat pad mass (VT:0010421)epididymal fat pad weight to body weight ratio (CMO:0000658)1455624247100624247Rat
2317879Alcrsp27Alcohol response QTL 273.30.63response to alcohol trait (VT:0010489)duration of loss of righting reflex (CMO:0002289)1456631369101631369Rat
634328Hc5Hypercalciuria QTL 52.3urine calcium amount (VT:0002985)urine calcium excretion rate (CMO:0000763)1458184885103184885Rat
70153Bp59Blood pressure QTL 593.2arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)146875779683368335Rat
1582259Gluco23Glucose level QTL 233.10.0008blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1470053989104886043Rat
1641900Alcrsp11Alcohol response QTL 11alcohol metabolism trait (VT:0015089)blood ethanol level (CMO:0000535)1470053989104886043Rat
1582197Gluco27Glucose level QTL 273.40.0006blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)147341532392554092Rat
1582209Gluco20Glucose level QTL 203.80.0005blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)147341532392554092Rat
1582236Gluco22Glucose level QTL 223.30.0164blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)147341532392554092Rat
1582255Gluco29Glucose level QTL 293.10.0025blood glucose amount (VT:0000188)absolute change in blood glucose level area under curve (CMO:0002034)147341532392554092Rat
1582250Gluco26Glucose level QTL 263.30.0009blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)147341532395876975Rat
631213Bw60Body weight QTL604.51retroperitoneal fat pad mass (VT:0010430)retroperitoneal fat pad weight to body weight ratio (CMO:0000635)147995092195876975Rat
4889951Bss92Bone structure and strength QTL 923.9tibia area (VT:1000281)tibia-fibula cortical bone total cross-sectional area (CMO:0001721)148205747195876975Rat

Markers in Region
Rat AssemblyChrPosition (strand)SourceJBrowse
Rnor_5.01481,093,177 - 81,093,349NCBIRnor5.0
RGSC_v3.41487,960,344 - 87,960,515RGDRGSC3.4
RGSC_v3.11487,979,489 - 87,979,660RGD
RH 3.4 Map14598.6UniSTS
RH 3.4 Map14598.6RGD
RH 2.0 Map14719.0RGD
Cytogenetic Map14q21UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21482,057,471 - 82,057,735 (+)MAPPERmRatBN7.2
Rnor_6.01487,458,772 - 87,459,035NCBIRnor6.0
Rnor_5.01481,093,112 - 81,093,375UniSTSRnor5.0
RGSC_v3.41487,960,277 - 87,960,541RGDRGSC3.4
RGSC_v3.41487,960,278 - 87,960,541UniSTSRGSC3.4
RGSC_v3.11487,979,422 - 87,979,686RGD
Celera1481,131,893 - 81,132,138UniSTS
RH 3.4 Map14602.4UniSTS
RH 3.4 Map14602.4RGD
RH 2.0 Map14719.4RGD
Cytogenetic Map14q21UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21482,057,486 - 82,057,735 (+)MAPPERmRatBN7.2
Rnor_6.01487,458,787 - 87,459,035NCBIRnor6.0
Rnor_5.01481,093,127 - 81,093,375UniSTSRnor5.0
RGSC_v3.41487,960,292 - 87,960,541RGDRGSC3.4
RGSC_v3.41487,960,293 - 87,960,541UniSTSRGSC3.4
RGSC_v3.11487,979,437 - 87,979,686RGD
Celera1481,131,908 - 81,132,138UniSTS
Cytogenetic Map14q21UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21482,057,518 - 82,057,712 (+)MAPPERmRatBN7.2
Rnor_6.01487,458,819 - 87,459,012NCBIRnor6.0
Rnor_5.01481,093,159 - 81,093,352UniSTSRnor5.0
RGSC_v3.41487,960,324 - 87,960,518RGDRGSC3.4
RGSC_v3.41487,960,325 - 87,960,518UniSTSRGSC3.4
RGSC_v3.11487,979,469 - 87,979,663RGD
Celera1481,131,940 - 81,132,115UniSTS
Cytogenetic Map14q21UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
RH 3.4 Map14593.7UniSTS
Cytogenetic Map14q21UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
Cytogenetic Map14q21UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21482,056,472 - 82,056,654 (+)MAPPERmRatBN7.2
Rnor_6.01487,457,773 - 87,457,954NCBIRnor6.0
Rnor_5.01481,092,113 - 81,092,294UniSTSRnor5.0
RGSC_v3.41487,959,279 - 87,959,460UniSTSRGSC3.4
Celera1481,130,894 - 81,131,075UniSTS
RH 3.4 Map14598.5UniSTS
Cytogenetic Map14q21UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21482,058,712 - 82,060,338 (+)MAPPERmRatBN7.2
Rnor_6.01487,460,013 - 87,461,638NCBIRnor6.0
Rnor_5.01481,094,353 - 81,095,978UniSTSRnor5.0
RGSC_v3.41487,961,519 - 87,963,144UniSTSRGSC3.4
Celera1481,133,116 - 81,134,741UniSTS
Cytogenetic Map14q21UniSTS


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
Medium 3 40 52 40 15 40 2 3 41 35 35 11 2
Low 3 5 1 4 1 6 8 33 6 6
Below cutoff


RefSeq Acc Id: ENSRNOT00000088355   ⟹   ENSRNOP00000073137
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1482,056,347 - 82,064,083 (-)Ensembl
Rnor_6.0 Ensembl1487,457,647 - 87,465,374 (-)Ensembl
RefSeq Acc Id: NM_012588   ⟹   NP_036720
RefSeq Status: VALIDATED
Rat AssemblyChrPosition (strand)Source
mRatBN7.21482,056,347 - 82,064,083 (-)NCBI
Rnor_6.01487,457,647 - 87,465,374 (-)NCBI
Rnor_5.01481,091,987 - 81,099,675 (-)NCBI
RGSC_v3.41487,959,153 - 87,967,085 (-)RGD
Celera1481,130,767 - 81,138,473 (-)NCBI
RefSeq Acc Id: NP_036720   ⟸   NM_012588
- Peptide Label: precursor
- UniProtKB: P15473 (UniProtKB/Swiss-Prot),   A0A0G2K4Q9 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000073137   ⟸   ENSRNOT00000088355
Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P15473-F1-model_v2 AlphaFold P15473 1-292 view protein structure


eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

RGD ID:13699484
Promoter ID:EPDNEW_R10007
Type:single initiation site
Description:insulin-like growth factor binding protein 3
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Rat AssemblyChrPosition (strand)Source
Rnor_6.01487,465,390 - 87,465,450EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2874 AgrOrtholog
BioCyc Gene G2FUF-15047 BioCyc
Ensembl Genes ENSRNOG00000061910 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000088355 ENTREZGENE
  ENSRNOT00000088355.2 UniProtKB/TrEMBL
Gene3D-CATH UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  4.10.800.10 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro Growth_fac_rcpt_cys_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  IGFBP-3 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  IGFBP-like UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  IGFBP_1-6_chordata UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Insulin_GF-bd_Cys-rich_CS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Thyroglobulin_1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Thyroglobulin_1_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:24484 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PTHR11551:SF3 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam IGFBP UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Thyroglobulin_1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Igfbp3 PhenoGen
  IGFBPFAMILY3 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PROSITE IGFBP_N_1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  IGFBP_N_2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  THYROGLOBULIN_1_1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  THYROGLOBULIN_1_2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
RatGTEx ENSRNOG00000061910 RatGTEx
SMART SM00121 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SM00211 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP SSF57184 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF57610 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
TIGR TC228669

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2004-02-26 Igfbp3  insulin-like growth factor binding protein 3      Symbol and Name status set to approved 625702 APPROVED
2002-06-10 Igfbp3  insulin-like growth factor binding protein 3      Name updated 70585 PROVISIONAL

RGD Curation Notes
Note Type Note Reference
gene_expression expressed in beating rat heart 628539
gene_function binds to Insulin-like growth factors (IGF) 70266
gene_mutations_overexpression overexpression in basal epithelium of prostate leads to spontaneous hyperplasia. 70266
gene_process controls distribution of IGFs 70266
gene_process binds to microvessel endothelial cells during perfusion through the heart which helps in the transport of IGF1 to cardiac muscle 628539
gene_process plays modulatory roles in type I fiber-dominated muscles, aging, and regrowth from atrophy 729113
gene_regulation expression in GH4C1 pituitary tumor cells is induced by 17-beta estradiol (E2) and triiodothryonine (T3) at low cell population density 1358947
gene_transcript cleaved by Prostate Specific Antigen (PSA) in humans 70266